{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:14:54Z","timestamp":1793128494909,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National High-tech R&D Program","award":["2006AA02Z339"],"award-info":[{"award-number":["2006AA02Z339"]}]},{"name":"Guangzhou Science and Technology Bureau","award":["2008AA02Z314"],"award-info":[{"award-number":["2008AA02Z314"]}]},{"name":"Guangzhou Development District","award":["2006Ss-P067"],"award-info":[{"award-number":["2006Ss-P067"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jpba.2015.08.033","type":"journal-article","created":{"date-parts":[[2015,8,29]],"date-time":"2015-08-29T18:43:12Z","timestamp":1440873792000},"page":"99-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Determination of a novel dipeptidyl peptidase IV inhibitor in monkey plasma by HPLC\u2013MS\/MS and its application in a pharmacokinetics study"],"prefix":"10.1016","volume":"117","author":[{"given":"Jifeng","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renke","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9491-1336","authenticated-orcid":false,"given":"Hui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2015.08.033_bib0005","unstructured":"International diabetes federation. http:\/\/www.idf.org\/"},{"issue":"6865","key":"10.1016\/j.jpba.2015.08.033_bib0010","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/414821a","article-title":"New drug targets for type 2 diabetes and the metabolic syndrome","volume":"414","author":"Moller","year":"2001","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jpba.2015.08.033_bib0015","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s001250050664","article-title":"Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM","volume":"40","author":"Rachman","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.jpba.2015.08.033_bib0020","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s001250051445","article-title":"Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7\u201336 amide) concentrations and improves oral glucose tolerance in obese Zucker rats","volume":"42","author":"Balkan","year":"1999","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.jpba.2015.08.033_bib0025","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.jpba.2015.08.033_bib0030","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide glucagon-like peptide-1(7-36) amide peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"Mentlein","year":"1993","journal-title":"Eur. J. Biochem."},{"issue":"12","key":"10.1016\/j.jpba.2015.08.033_bib0035","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.2337\/diacare.27.12.2874","article-title":"Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes","volume":"27","author":"Ahren","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jpba.2015.08.033_bib0040","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1210\/jc.2003-031907","article-title":"Inhibition of dipeptidyl peptidase-4 reduces glycemia sustains insulin levels and reduces glucagon levels in type 2 diabetes","volume":"89","author":"Ahren","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.jpba.2015.08.033_bib0045","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.2337\/diacare.28.8.1936","article-title":"Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year","volume":"28","author":"Ahren","year":"2005","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jpba.2015.08.033_bib0050","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2337\/diacare.25.5.869","article-title":"Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes","volume":"25","author":"Ahren","year":"2002","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jpba.2015.08.033_bib0055","doi-asserted-by":"publisher","first-page":"764","DOI":"10.2337\/diabetes.47.5.764","article-title":"Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig","volume":"47","author":"Deacon","year":"1998","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.jpba.2015.08.033_bib0060","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2337\/diabetes.47.11.1663","article-title":"Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes","volume":"47","author":"Holst","year":"1998","journal-title":"Diabetes"},{"issue":"5\u20136","key":"10.1016\/j.jpba.2015.08.033_bib0065","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.biocel.2005.09.011","article-title":"Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes","volume":"38","author":"Deacon","year":"2006","journal-title":"Int. J. Biochem. Cell. Biol."},{"issue":"6","key":"10.1016\/j.jpba.2015.08.033_bib0070","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2174\/156802607780091028","article-title":"Discovery of JANUVIA (Sitagliptin): a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"7","author":"Thornberry","year":"2007","journal-title":"Curr. Top Med. Chem."},{"issue":"2","key":"10.1016\/j.jpba.2015.08.033_bib0075","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bcp.2009.03.032","article-title":"Biochemistry pharmacokinetics and toxicology of a potent and selective DPP8\/9 inhibitor","volume":"78","author":"Wu","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.jpba.2015.08.033_bib0080","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/dc06-1732","article-title":"Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin","volume":"30","author":"Bosi","year":"2007","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.jpba.2015.08.033_bib0085","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1210\/jc.2007-1639","article-title":"Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia","volume":"93","author":"Mari","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.jpba.2015.08.033_bib0090","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1517\/14656560802694713","article-title":"Alogliptin:a new highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes","volume":"10","author":"Pratley","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jpba.2015.08.033_bib0095","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejmech.2010.10.016","article-title":"The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes","volume":"46","author":"Deng","year":"2011","journal-title":"Eur J Med Chem :."},{"key":"10.1016\/j.jpba.2015.08.033_bib0100","article-title":"Guidance for industry","author":"FDA","year":"2001","journal-title":"Bioanal. Method Validation"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851530131X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851530131X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T20:34:57Z","timestamp":1567110897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170851530131X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":20,"alternative-id":["S073170851530131X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2015.08.033","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of a novel dipeptidyl peptidase IV inhibitor in monkey plasma by HPLC\u2013MS\/MS and its application in a pharmacokinetics study","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2015.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}